title: [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
abstract: 146 patients with multiple sclerosis are treated by copaxone in the Moscow MS Centre. The relaps exacerbation rate decreased by 72%, the relapse rate reduced by 25.6% during the copaxone treatment. EDSS score did not increase both in group with and without relapses. The condition of 2/3 patients was stable. To achieve the best effect of treatment the program of patient support was successfully used in the Moscow MS Centre.
authors.forename: T L
authors.initials: TL
authors.lastname: Demina
authors.forename: M V
authors.initials: MV
authors.lastname: Davydovskaia
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Lashch
authors.forename: N F
authors.initials: NF
authors.lastname: Popova
authors.forename: N V
authors.initials: NV
authors.lastname: Khachanova
authors.forename: T D
authors.initials: TD
authors.lastname: Zhuchenko
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001369:Axons / Q000473:pathology; D001921:Brain / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D000068717:Glatiramer Acetate; D006684:HLA-DR Antigens / Q000187:drug effects / Q000276:immunology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy* / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D006684:HLA-DR Antigens; D010455:Peptides; D000068717:Glatiramer Acetate